Abstract: The invention relates to treatments of cognitive disorders e.g. Mild Cognitive Disorder comprising the use of agents which are capable of lowering homocysteine levels in a subject, preferably a human subject. Aspects of the invention relate to a method of treating such disorders comprising administering one or more B vitamins e.g. folic acid, Vitamin B6 and/or Vitamin B12 or derivatives thereof.

Abstract: The invention relates to the use of a mono-, di- or tri-glyceride of citric acid, or a derivative thereof, as a clathrate hydrate adhesion reducer in a surface coating composition. The mono-, di- or tri glyceride of citric acid is preferably a mono-glyceride in which the fatty acid is a monocarboxylic acid having a branched or unbranched, saturated or unsaturated, aliphatic chain comprising between 12 and 20 carbon atoms, particularly oleic, linolenic, stearic or erucic acid. The surface coating composition can be used to coat at least part of a surface of an assembly for use in hydrocarbon production, transportation, storage or processing.

Abstract: The invention relates to treatments of cognitive disorders e.g. Mild Cognitive Disorder comprising the use of agents which are capable of lowering homocysteine levels in a subject, preferably a human subject. Aspects of the invention relate to a method of treating such disorders comprising administering one or more B vitamins e.g. folic acid, Vitamin B6 and/or Vitamin B12 or derivatives thereof.

Abstract: The invention relates to a method of operating a hybrid internal combustion engine, which method comprises: fuelling said hybrid internal combustion engine with a combustible fuel; lubricating said engine with an engine oil composition; and maintaining an oil film thickness of the engine oil composition in the big end conrod bearing shells of the engine of at least 0.4 ?m; in which the temperature of the engine oil composition is maintained below 123° C. and the engine oil composition has: a high temperature, high shear viscosity of less than 2.6 cP (2.6 millipascal second) at 150° C. and at a shear rate of 106 s?1; a Noack volatility of at most 13 weight %; and comprises: (A) a base oil which is at least one synthetic basestock, the base oil having a kinematic viscosity of at least 2.0 cSt (2.0 mm2/s) at 100 ° C.

Abstract: An access control device including electronic identification device, the access control device characterized in that the access control device also includes an audio communication device.

Abstract: A method is provided for treating occlusive vascular disease or Alzheimer's disease, wherein the patient has at least moderately elevated blood levels of homocysteine and at least moderately reduced blood levels of folate and vitamin B.sub.12, wherein the patient is treated with folic acid, a folate or a derivative thereof, and optionally vitamin B.sub.12, and optionally an organic nitrate such as isosorbide mononitrate or dinitrate, or an ACE inhibitor or an angiotensin II antagonist, or a NEP/ACE inhibitor or a combination of two or more of the above.

Abstract: A method is provided for determining the propensity or predisposition of a human subject to develop late-onset Alzheimer's disease by the presence in a human subject of a gene (1) for butyrylcholinesterase K variant, and a gene (2) for apolipoprotein E4, the presence of the gene (1) or the presence of both of the above genes (1) and (2) indicating a propensity or predisposition to develop late-onset Alzheimer's disease.

Abstract: A method is provided for treating occlusive vascular disease or Alzheimer's disease, wherein the patient has at least moderately elevated blood levels of homocysteine and at least moderately reduced blood levels of folate and vitamin B.sub.12, wherein the patient is treated with folic acid, a folate or a derivative thereof, and optionally vitamin B.sub.12, and optionally an organic nitrate such as isosorbide mononitrate or dinitrate, or an ACE inhibitor or an angiotensin II antagonist, or a NEP/ACE inhibitor or a combination of two or more of the above.